Breaking News Instant updates and real-time market news.

AAPL

Apple

$168.37

-6.37 (-3.65%)

, QCOM

Qualcomm

$56.00

-1.1 (-1.93%)

09:19
12/10/18
12/10
09:19
12/10/18
09:19

Fly Intel: Pre-market Movers

HIGHER: Nutrisystem (NTRI), up 33% after Tivity Health (TVTY) agreed to acquire all of the outstanding shares of Nutrisystem for a combination of cash and stock valued at $47.00 per share... Axsome Therapeutics (AXSM), up 15% after the Independent Data Monitoring Committee recommended continuation of its trial evaluating AXS-05 in Alzheimer's disease... Mitek Systems (MITK), up 16% after ASG Technologies increased its offer to $11.50 per share to acquire the company... RA Pharmaceuticals (RARX), up 7% after its Phase 2 trial of zilucoplan met its primary endpoint... Marinus Pharmaceuticals (MRNS), up 9% after announcing it is advancing both ganaxolone studies into the next phase of development to evaluate IV and oral dose regimens... Travelport (TVPT), up 1%, after the company agreed to be acquired by affiliates of Siris Capital and Evergreen Coast Capital in an all-cash transaction valued at approximately $4.4B. LOWER: Apple (AAPL), down 2% after Qualcomm (QCOM) announced that the Fuzhou Intermediate People's Court in China has granted the company's request for two preliminary injunctions, ordering Apple to immediately cease infringing upon two Qualcomm patents through the unlicensed importation, sale and offers for sale in China of the iPhone 6S, iPhone 6S Plus, iPhone 7, iPhone 7 Plus, iPhone 8, iPhone 8 Plus and iPhone X... Axovant Sciences (AXON), down 23% after announcing its nelotanserin Phase 2 study does not meet its primary endpoint... Navistar (NAV) and Oshkosh (OSK), down 4% and 2%, respectively, after Goldman Sachs analyst Jerry Revich downgraded the stocks to Sell from Neutral as part of his broader research note on the Engineering & Construction sector... MacroGenics (MGNX), down 21% after the FDA placed a partial hold on two studies involving MGD009...

AAPL

Apple

$168.37

-6.37 (-3.65%)

QCOM

Qualcomm

$56.00

-1.1 (-1.93%)

NTRI

Nutrisystem

$34.19

-1.07 (-3.03%)

AXSM

Axsome Therapeutics

$2.97

-0.17 (-5.41%)

MITK

Mitek Systems

$8.98

-0.12 (-1.32%)

RARX

RA Pharmaceuticals

$16.45

0.25 (1.54%)

MRNS

Marinus Pharmaceuticals

$5.18

-0.12 (-2.26%)

TVPT

Travelport

$15.40

-0.32 (-2.04%)

AXON

Axovant Sciences

$1.72

-0.05 (-2.82%)

NAV

Navistar

$28.73

-1.32 (-4.39%)

OSK

Oshkosh

$66.69

-1.38 (-2.03%)

MGNX

MacroGenics

$16.44

-0.15 (-0.90%)

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

AAPL Apple
$168.37

-6.37 (-3.65%)

12/10/18
KEYB
12/10/18
NO CHANGE
KEYB
Sector Weight
Apple XR softness suggests troubles in 'pricing land,' says KeyBanc
KeyBanc analyst Andy Hargreaves says supply and demand checks suggest soft iPhone XR demand and a much larger tendency to trade down to older models than he expected. This prompts a shift to his mix assumptions and, more importantly, suggests Apple is hitting the limits of pricing power for a large portion of its user base, he contends. The analyst believes that this is likely to present a challenge to growth over a multi-year time frame that prevents him from a more positive opinion of the shares. Hargreaves reiterates a Sector Weight rating on the shares.
12/07/18
OTRG
12/07/18
NO CHANGE
OTRG
Phone buyer sources point to cuts in Apple iPhone XR orders, says OTR Global
OTR Global said its checks indicate that smartphone buyers and managers at network operators, retailers and distributors in China, Europe and India have mostly reduced their 1Q19 orders for Apple's iPhone XR as sell-through in Q4 has fallen below expectations. 13 of 15 Asian sources reported oversupply for iPhone XR and 4 of 7 Chinese sources noted reduced iPhone XR retail prices, OTR added.
12/10/18
12/10/18
DOWNGRADE

Sector Weight
Qorvo downgraded to Sector Weight at KeyBanc after demand checks
As previously reported, KeyBanc analyst Weston Twigg downgraded Qorvo (QRVO) to Sector Weight from Overweight given further weakening Apple (AAPL) iPhone demand trends, weaker than expected China smartphone demand, and indications Qualcomm (QCOM) is finally gaining market share on RF360 amid transition to 5G in 2H19. While the analyst believes Qorvo remains well positioned for 5G longer term and sees modest downside risk with the stock trading near trough valuation, Twigg struggles to see positive catalysts given the disappointing iPhone cycle and weakening demand environment for China smartphones. Overall, his quarterly Asia supply chain findings and demand checks left him incrementally more cautious on the semiconductor space.
12/10/18
KEYB
12/10/18
DOWNGRADE
KEYB
Sector Weight
Skyworks downgraded to Sector Weight at KeyBanc on weakening smartphone demand
As previously reported, KeyBanc analyst Weston Twigg downgraded Skyworks (SWKS) to Sector Weight from Overweight given further weakening Apple (AAPL) iPhone demand trends, weaker than expected China smartphone demand, indications Qualcomm (QCOM) is finally gaining market share on RF360 amid transition to 5G in 2H19, and modest share lost in China smartphones to Qorvo (QRVO) this year as a result of RF Fusion phase 6 and signs of supply constraints at Skyworks. While the analyst believes Skyworks remains well positioned for 5G longer term and sees modest downside risk with the stock trading near trough valuation, Twigg struggles to see positive catalysts given the disappointing iPhone cycle and weakening demand environment for China smartphones.
QCOM Qualcomm
$56.00

-1.1 (-1.93%)

12/03/18
MSCO
12/03/18
NO CHANGE
Target $100
MSCO
Equal Weight
Morgan Stanley says 'a lot has changed' since Qualcomm first bid to buy NXP
After the White House issued a statement that noted Chinese President Xi said he is open to approving Qualcomm's (QCOM) previous bid to buy NXP Semiconductors (NXPI) if it were presented to him again, Morgan Stanley analyst Craig Hettenbach noted that "a lot has changed" since Qualcomm's initial offer. The semiconductor industry was in the midst of an upcyle at that time, but it is now in the midst of a correction that will likely mean downward estimate revision risk in 2019, Hettenbach said. If NXP were presented with another offer, he thinks the board could be open to the idea, but would likely require greater certainty of approval before committing given that the drawn out approval process was a material overhang last time. Hettenbach maintains an Equal Weight rating on NXP shares with a $100 price target.
12/06/18
SUSQ
12/06/18
INITIATION
Target $90
SUSQ
Neutral
NXP Semiconductors initiated with a Neutral at Susquehanna
Susquehanna analyst Chris Roland initiated NXP Semiconductors (NXPI) with a Neutral rating and a price target of $90. The analyst expects the company to benefit from its "substantial auto exposure" but also warns that trade tensions, soft auto sales, and "contracting industry lead times" warrant a near-term pause. Roland adds that once the "Qualcomm (QCOM) hangover" subsides, NXP Semiconductors revenue will re-accelerate as the company refocuses on its core business. The analyst is further positive on the company's "diversification away from Apple (AAPL) and handsets, and focus on new growth opportunities including high-power RF's in 5G infrastructure".
NTRI Nutrisystem
$34.19

-1.07 (-3.03%)

11/01/18
DADA
11/01/18
UPGRADE
DADA
Neutral
Nutrisystem upgraded to Neutral from Underperform at DA Davidson
11/01/18
11/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nutrisystem (NTRI) upgraded to Outperform from Market Perform at Barrington and to Neutral from Underperform at DA Davidson. 2. SeaWorld (SEAS) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brett Andress saying de-risked expectations following the Q3 pre-announcement create an attractive entry point, as he sees further upside to shares, with his confidence in the company's turnaround bolstered by additional evidence of both a brand and business in recovery mode. 3. Sanofi (SNY) upgraded to Equal Weight from Underweight at Barclays with analyst Emmanuel Papadakis saying he sees a more balanced risk/reward profile at current share levels. 4. Asur (ASR) upgraded to Overweight from Neutral at JPMorgan with analyst Fernando Abdalla citing valuation. 5. Wex (WEX) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/18
DADA
11/01/18
UPGRADE
Target $36
DADA
Neutral
Nutrisystem upgraded to Neutral at DA Davidson on reduced cost outlook
As reported earlier, DA Davidson analyst Linda Bolton Weiser upgraded Nutrisystem to Neutral from Underperform and raised her price target to $36 from $27 after its Q3 results. The analyst notes that while the company lowered the midpoint of its 2018 EBITDA guidance range, it anticipates an EBITDA growth of up to 33% in Q4 through lower marketing and G&A expense costs. Weiser adds that her downgrade on October 15th reflected "continuing steep price discounts to reactivation customers and potential weakening of South Beach performance", but at this time, she sees no other near-term catalyst that would justify expectations of further multiple contraction.
11/01/18
BRRR
11/01/18
UPGRADE
Target $44
BRRR
Outperform
Nutrisystem upgraded to Outperform from Market Perform at Barrington
Barrington analyst Chris Howe upgraded Nutrisystem to Outperform from Market Perform, stating that the company has made significant improvements despite the last diet season having been disappointing. He points to better brand strength, creative for television and digital, expanded reach via digital acceleration and media efficiency. Howe set a $44 price target on Nutrisystem shares.
AXSM Axsome Therapeutics
$2.97

-0.17 (-5.41%)

10/17/18
LTCO
10/17/18
NO CHANGE
Target $34
LTCO
Buy
Axsome Therapeutics price target raised to $34 from $29 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan raised his price target for Axsome Therapeutics to $34 after the company said it plans to initiate a Phase 2 trial of AXS-12 for the treatment of the symptoms of narcolepsy in Q4 with top-line results anticipated in the first half of 2019. The analyst notes that there are only five approved compounds for the treatment of narcolepsy and only one for the treatment of both excessive daytime sleepiness and cataplexy. Including AXS-12 added $5 per share to Kaplan's model and he reiterates a Buy rating on Axsome Therapeutics.
12/05/18
HCWC
12/05/18
NO CHANGE
Target $10
HCWC
Buy
Axsome Therapeutics approaching several catalyts, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju noted that management at Axsome Therapeutics expect interim data from the STRIDE-1 trial of AXS-05 in TRD, interim data from the ADVANCE-1 trial of AXS-05 in AD-associated agitation and top-line data from the Phase 2 ASCEND trial of AXS-05 in major depressive disorder, all in the fourth quarter of 2018. He believes that positive data in TRD should have favorable read-through to the MDD indication sees Axsome's pivotal migraine study with AXS-07 starting before year-end and producing top-line data in 2019. Ahead of these upcoming "key value inflection points," Selvaraju reiterated his Buy rating and $10 price target on Axsome shares.
11/15/18
CANT
11/15/18
INITIATION
Target $16
CANT
Overweight
Axsome Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Axsome Therapeutics with an Overweight rating and $16 price target. The analyst rolled out coverage on five Neuro-Innovator companies, focusing on "innovative technologies that can lead to breakthrough and disruptive treatments." He believes all five companies have "growth potential that exceeds current valuations, over time."
11/14/18
CANT
11/14/18
INITIATION
Target $16
CANT
Overweight
Axsome Therapeutics resumed with an Overweight at Cantor Fitzgerald
Price target $16.
MITK Mitek Systems
$8.98

-0.12 (-1.32%)

10/26/18
BNCH
10/26/18
NO CHANGE
BNCH
Hold
Mitek poison pill evidence it has no interest in being acquired, says Benchmark
Benchmark analyst Mark Schappel called Mitek Systems' shareholder rights plan "essentially a poison pill" that he sees being aimed at fending off a takeover by ASG Technologies, which is backed by Elliott Management. He views the rights plan as further evidence that Mitek has no interest in entertaining an acquisition by Elliott and he keeps a Hold rating on the shares.
11/27/18
BNCH
11/27/18
UPGRADE
Target $12
BNCH
Buy
Mitek Systems upgraded to Buy from Hold at Benchmark
Benchmark analyst Mark Schappel upgraded Mitek Systems to Buy with a $12 price target. The analyst believes the rescinded resignation of CFO Jeffrey Davison removes a hurdle for the company.
08/28/18
08/28/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mitek Systems (MITK) downgraded to Hold from Buy at Benchmark with analyst Mark Schappel saying recent management departures leave uncertainty in key roles. 2. Control4 (CTRL) downgraded to In-Line from Outperform at Imperial Capital with analyst Saliq Khan citing valuation. 3. Applied Materials (AMAT) and Lam Research (LRCX) were downgraded to Neutral from Buy at BofA/Merrill. 4. DDR Corp. (DDR) downgraded to Hold from Buy at Deutsche Bank. 5. Newtek Business Services (NEWT) downgraded to Underperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/18
BNCH
11/27/18
UPGRADE
Target $12
BNCH
Buy
Benchmark upgrades Mitek to Buy, sees CFO about-face helping to fend off Elliott
As previously reported, Benchmark analyst Mark Schappel upgraded Mitek Systems to Buy from Hold with a $12 price target. The analyst views CFO Jeffrey Davison rescinding his resignation and agreeing to stay on as a vote of confidence in new CEO Max Carnecchia and believes filling the CFO vacancy was one of the remaining hurdles in the company's attempt to fend-off the pending takeover proposal from Elliott. Given his view that Mitek is now better positioned to fend off Elliott's $10 per share proposal, Schappel thinks the activist will either need to up its offer meaningfully, drop its bid altogether or formulate additional steps such as proposing a dissident slate of directors.
RARX RA Pharmaceuticals
$16.45

0.25 (1.54%)

07/20/18
BMOC
07/20/18
INITIATION
Target $20
BMOC
Outperform
RA Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini initiated RA Pharmaceuticals with an Outperform rating and $20 price target.
08/08/18
RAJA
08/08/18
NO CHANGE
Target $28
RAJA
Outperform
RA Pharmaceuticals price target raised to $28 from $18 at Raymond James
10/10/18
RAJA
10/10/18
UPGRADE
RAJA
Strong Buy
RA Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
MRNS Marinus Pharmaceuticals
$5.18

-0.12 (-2.26%)

07/19/18
MZHO
07/19/18
NO CHANGE
Target $13
MZHO
Buy
Marinus can rally 100% on postpartum depression data, says Mizuho
Mizuho analyst Difei Yang believes Marinus Pharmaceuticals' Q3 top-line data from part 1 of the Phase 2 Magnolia study of ganaxolone IV in women with postpartum depression will be an "important catalyst" for the shares. The analyst sees upside potential of 100%-plus, assuming "convincing data including a clear dose response." She believes the downside is limited given the history of the compound and potential in other indications. Yang reiterates a Buy rating on Marinus with a $13 price target.
07/02/18
CANT
07/02/18
INITIATION
Target $19
CANT
Overweight
Marinus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros started Marinus Pharmaceuticals with an Overweight rating and $19 price target. The analyst views the stock's risk/reward as compelling into upcoming data catalysts for ganaxolone, a positive allosteric modulator of GABAA receptor.
05/24/18
05/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) initiated with an Outperform at Evercore ISI. 2. Caesars (CZR) initiated with an Overweight at JPMorgan. 3. e.l.f. Beauty (ELF) initiated with an Outperform at Oppenheimer. 4. uniQure (QURE) initiated with a Buy at SunTrust. 5. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/18
LTCO
06/06/18
INITIATION
Target $20
LTCO
Buy
Marinus Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Michael Higgins started Marinus Pharmaceuticals with a Buy rating and $20 price target.
TVPT Travelport
$15.40

-0.32 (-2.04%)

08/03/18
BOFA
08/03/18
DOWNGRADE
Target $17
BOFA
Underperform
Travelport downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst John King downgraded Travelport to Underperform from Neutral and cut its price target to $17 from $20. King said valuation has run ahead of fundamentals following the Q2 report and expects the loss of Tripsta in Greece to pressure volume growth in 2H 2018.
11/02/18
IMPC
11/02/18
NO CHANGE
Target $20
IMPC
Outperform
Travelport price target lowered to $20 from $25 at Imperial Capital
Imperial Capital analyst Adam Hackel lowered his price target for Travelport to $20 following the company's Q3 results but maintains an Outperform rating on the name. The reaffirmed its fiscal year guidance following the better than expected Q3 results, while acknowledging headwinds in Q4 and early fiscal 2019, Hackel tells investors in a post-earnings research note. Despite "some near-term headwinds," Travelport shares are attractive, says the analyst.
09/06/18
DBAB
09/06/18
NO CHANGE
Target $25
DBAB
Buy
Travelport should sell eNett in near future, says Deutsche Bank
eNett could be valued at $1B and Travelport (TVPT) could use the proceeds from a divestiture for an accelerated share repurchase or potentially lower the equity required to take the company private, Deutsche Bank analyst Ashish Sabadra tells investors in a research note. The analyst believes Travelport is not being valued on a sum-of-the-parts basis and that it is not given credit for the accelerated growth in eNett. Given the "rich valuation for high-growth payment assets," Travelport should sell eNett in the near future, Sabadra contends. The analyst believes an acquisition of eNett could potentially complement Wex's (WEX) Travel and Corporate payments offering and could also be synergistic with Fleetcor's (FLT) corporate payment business. Sabadra has a Buy rating on Travelport with a $25 price target.
05/15/18
05/15/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ford (F) downgraded to Neutral from Overweight at Piper Jaffray with analyst Alexander Potter saying that while stock's valuation still appears low, relative to other stocks he covers, he's less convinced that Ford "can find compelling revenue drivers to offset secular threats." 2. aTyr Pharma (LIFE) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying a lack of clinical data and early stage of understanding for lead agent ATYR1923 create a low probability of success. 3. ClearOne (CLRO) downgraded to Neutral from Buy at B. Riley FBR. 4. Travelport (TVPT) downgraded to Neutral on valuation at BofA/Merrill with analyst John King citing relative valuation. 5. W&T Offshore (WTI) downgraded to Sell from Hold at KLR Group with analyst Gail Nicholson citing the stock's out-performance of the SPDR Oil Exploration and Production Fund (XOP) by about 54% over the last month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AXON Axovant Sciences
$1.72

-0.05 (-2.82%)

01/12/18
COWN
01/12/18
DOWNGRADE
COWN
Market Perform
Axovant Sciences downgraded to Market Perform from Outperform at Cowen
01/12/18
01/12/18
DOWNGRADE

Market Perform
Axovant Sciences downgraded after intepirdine failure at Cowen
As previously reported, Cowen analyst Ritu Baral downgraded Axovant Sciences to Market Perform from Outperform following the failure of the HEADWAY and Gait studies for intepirdine. Additionally, nelotanserin data have deteriorated since a mid-2017 interim look, added Baral, who now sees Axovant "as a SPAC," or special purpose acquisition company, with "limited clarity."
06/11/18
JEFF
06/11/18
NO CHANGE
Target $5
JEFF
Hold
Axovant Sciences price target raised to $5 from $3 at Jefferies
Following Axovant Sciences' in-licensing of AXO-Lenti-PD, Jefferies analyst Michael Yee said he thinks the asset is "interesting" and looks forward to new data potentially 2019, but he also appreciates the stock has already had a big move and it may take some time to create new value. Yee, who thinks the company has cash to do deals and may add yet another product this year, raised his price target on Axovant shares to $5 from $3 and keeps a Hold rating on the stock.
01/10/18
CHDN
01/10/18
UPGRADE
CHDN
Neutral
Axovant Sciences upgraded to Neutral from Sell at Chardan
Chardan analyst Gbola Amusa upgraded Axovant Sciences to Neutral from Sell citing share underperformance and lowered its price target to $2 from $2.50.
NAV Navistar
$28.73

-1.32 (-4.39%)

12/10/18
GSCO
12/10/18
DOWNGRADE
Target $23
GSCO
Sell
Navistar downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Jerry Revich downgraded Navistar International to Sell and lowered his price target for the shares to $23 from $43. The analyst recommends an increasingly selective approach for the Americas Machinery, Engineering & Construction sector in 2019 amid growing signs of oversupply.
12/10/18
GSCO
12/10/18
DOWNGRADE
Target $23
GSCO
Sell
Navistar downgraded to Sell at Goldman Sachs on peaking truck production
As reported earlier, Goldman Sachs analyst Jerry Revich downgraded Navistar to Sell from Neutral and lowered his price target to $23 from $43 as part of his broader research note on the Engineering & Construction sector which requires a more selective positioning amid "growing signs of oversupply". The analyst expects a downturn in U.S. truck production to become evident by the end of next year and weigh on margins, even though the business trades "at the high end of its historical enterprise value to EBITDA valuation range. Revich adds that while the US truck demand accelerated in 2016-17 amid a "sharp increase in spot rates born of low capital stock, low unemployment, and electronic logging standards that reduced effective capacity", supply has now caught up with demand.
12/05/18
JPMS
12/05/18
NO CHANGE
JPMS
Class 8 truck orders dropped 15% in November, says JPMorgan
Preliminary Class 8 truck orders for November fell 15% year-over-year to 27,900 units according to ACT Research, JPMorgan analyst Ann Duignan tells investors in a research note. The analyst points out that November represents the first year-over-year monthly decline in 2018. The names she covers that have the largest exposure to Class 8 truck orders are Navistar (NAV), Paccar (PCAR), Cummins (CMI), Eaton (ETN), Wabco (WBC) and Allison Transmission (ALSN).
12/06/18
LOOP
12/06/18
UPGRADE
Target $44
LOOP
Buy
Navistar upgraded to Buy from Hold at Loop Capital
Loop Capital analyst Jeffrey Kauffman upgraded Navistar to Buy from Hold and raised his price target to $44 from $42, saying his confidence in the company's prospects and strategic initiatives has increased even as the stock price has declined 22% since the start of Q4. The analyst contends that the pullback offers an "attractive entry opportunity", particularly given the management's efforts to "improve the company's financial and competitive position" and investors' lagging adjustment to reflect the market share gains. Kauffman adds that amid the pessimism of a peaking Class 8 truck cycle, an increasing component of Navistar's earnings is coming from medium duty trucks, with the negative cycle impact further dampened by the company's market share gains and improving operating performance.
OSK Oshkosh
$66.69

-1.38 (-2.03%)

09/05/18
DBAB
09/05/18
INITIATION
Target $77
DBAB
Hold
Oshkosh resumed with a Hold at Deutsche Bank
Deutsche Bank analyst Chad Dillard resumed coverage of Oshkosh with a Hold rating and $77 price target. Since late cycle concerns took hold in April, the Machinery sector has underperformed the S&P 500 by 15% and is approaching valuation lows last seen during the 2015 energy and 2008 global financial crises, Dillard tells investors in a research note. He resumed coverage of eight stocks in the Machinery sector, with two Buy ratings, one Sell rating and five Holds.
12/10/18
GSCO
12/10/18
DOWNGRADE
Target $58
GSCO
Sell
Oshkosh downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Jerry Revich downgraded Oshkosh to Sell and lowered his price target for the shares to $58 from $66. The analyst recommends an increasingly selective approach for the Americas Machinery, Engineering & Construction sector in 2019 amid growing signs of oversupply.
11/02/18
RHCO
11/02/18
NO CHANGE
Target $96
RHCO
Buy
Oshkosh price target lowered to $96 from $108 at SunTrust
SunTrust analyst Charles Brady lowered his price target on Oshkosh to $96 to reflect the "significant retreat" in its stock price ahead of Q4 earnings on concerns over "peaking Access Equipment business and margins from rising costs". The analyst raises his FY19 EPS view to $7.25 from $6.36 and FY20 to $8.33 from $7.70 following the Q4 earnings beat however, adding that the quarter's margins were especially strong and that the company has "more levers to pull on pricing and lean initiatives". Brady also keeps his Buy rating on Oshkosh.
12/10/18
GSCO
12/10/18
DOWNGRADE
Target $58
GSCO
Sell
Oshkosh downgraded to Sell at Goldman Sachs on peaking access equipment backlog
As reported earlier, Goldman Sachs analyst Jerry Revich downgraded Oshkosh to Sell from Neutral and lowered his price target to $58 from $66 as part of his broader research note on the Engineering & Construction sector which requires a more selective positioning amid "growing signs of oversupply". The analyst expects the company's "Aerial Platform orders to decline following a year of peak industry supply additions", which will drive comparable cycle pressure in the segment. Revich adds while that the bulls on the stock will point to the record length of backlog, orders are a more telling indicator of the Oshkosh run-rate demand for the next 6-12 months.
MGNX MacroGenics
$16.44

-0.15 (-0.90%)

12/04/18
RHCO
12/04/18
DOWNGRADE
Target $75
RHCO
Hold
Tesaro downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Tesaro (TSRO) to Hold from Buy and raised his price target to $75 from $65 after its announcement of being acquired by Glaxo SmithKline (GSK). The analyst believes that the $75 per share offer price is "fair" and expects the deal, which he views as potentially positive for peers and for the biotech tape, to be completed in Q1 of 2019. Lawson anticipates that other companies with DNA damage response targeting drugs such as Sierra Oncology (SRRA), as well as immunoefficiency pipeline peers including MacroGenics (MGNX), Array Biopharma (ARRY), and Deciphera Pharmaceuticals (DCPH) could benefit from the announcement.
12/10/18
RAJA
12/10/18
DOWNGRADE
RAJA
Underperform
MacroGenics downgraded to Underperform from Outperform at Raymond James
12/10/18
MSCO
12/10/18
NO CHANGE
MSCO
Equal Weight
MacroGenics hold doesn't impact other B7-H3 therapies, says Morgan Stanley
After MacroGenics announced the FDA has place a partial clinical hold on MGD009, Morgan Stanley analyst David Lebowitz noted that the hold is said to not impact other B7-H3 targeted therapies, including enoblituzumab and MGC018. Given MacroGenic's prior experience with flotetuzumab, he expects to see weakness in the shares on the open this morning, but Lebowitz points out that modifications for flotetuzumab allowed for better management of cytokine related AEs and that it continues to be studied. He keeps an Equal Weight rating on MacroGenics with a $21 price target. In pre-market trading, the stock is down $2.71, or 16.5%, to $13.70.
09/10/18
BTIG
09/10/18
INITIATION
Target $30
BTIG
Buy
MacroGenics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed MacroGenics with a Buy rating and a price target if $30, saying he is positive on its DART and TRIDENT multi-functional antibodies programs and its Fc Optimization technology that "allows antibodies to interact more strongly with immune effector cells that resolve antibody-antigen complexes". The analyst contends that while the company's monoclonal antibodies, or mAb, development space is "crowded", MacroGenics offers "nearly two decades of tough won experience" and over two years of cash runway to give its "deep pipeline" multiple opportunities to "turn heads".

TODAY'S FREE FLY STORIES

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:44
11/11/19
11/11
20:44
11/11/19
20:44
Earnings
Nesco Holdings cuts FY19 revenue view to $255M-$262M from $278M »

One estimate $279.6M. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:42
11/11/19
11/11
20:42
11/11/19
20:42
Earnings
Nesco Holdings reports Q3 EPS (45c), one estimate 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FTK

Flotek

$1.86

-0.1 (-5.10%)

20:29
11/11/19
11/11
20:29
11/11/19
20:29
Earnings
Flotek reports Q3 EPS (19c), one estimate (23c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RF

Regions Financial

$16.77

-0.1 (-0.59%)

20:27
11/11/19
11/11
20:27
11/11/19
20:27
Downgrade
Regions Financial rating change at BMO Capital »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

TSN

Tyson Foods

$82.70

0.12 (0.15%)

, ROK

Rockwell Automation

$180.00

2.25 (1.27%)

20:25
11/11/19
11/11
20:25
11/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TSN

Tyson Foods

$82.70

0.12 (0.15%)

ROK

Rockwell Automation

$180.00

2.25 (1.27%)

DHI

D.R. Horton

$52.65

1.535 (3.00%)

CBS

CBS

$39.21

1.09 (2.86%)

AAP

Advance Auto Parts

$168.41

1.17 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

RMTI

Rockwell Medical

$1.92

0.07 (3.78%)

20:01
11/11/19
11/11
20:01
11/11/19
20:01
Recommendations
Rockwell Medical analyst commentary at Piper Jaffray »

Rockwell Medical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

APYX

Apyx Medical

$7.22

0.24 (3.44%)

19:39
11/11/19
11/11
19:39
11/11/19
19:39
Recommendations
Apyx Medical analyst commentary at Piper Jaffray »

Apyx Medical price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

FOE

Ferro

$12.58

0.07 (0.56%)

, APYX

Apyx Medical

$7.22

0.24 (3.44%)

18:59
11/11/19
11/11
18:59
11/11/19
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ferro…

FOE

Ferro

$12.58

0.07 (0.56%)

APYX

Apyx Medical

$7.22

0.24 (3.44%)

KEM

Kemet

$23.03

-0.51 (-2.17%)

ICUI

ICU Medical

$168.41

1.43 (0.86%)

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

GO

Grocery Outlet

$31.09

-0.06 (-0.19%)

CMLS

Cumulus Media

$13.59

0.07 (0.52%)

FGEN

FibroGen

$35.37

-6.24 (-15.00%)

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

LYV

Live Nation

$64.47

1.31 (2.07%)

FLNT

Fluent

$2.54

0.11 (4.53%)

ASUR

Asure Software

$9.20

0.01 (0.11%)

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

FPI

Farmland Partners

$6.66

-0.125 (-1.84%)

RETA

Reata Pharmaceuticals

$213.52

1.48 (0.70%)

JCOM

j2 Global

$100.62

0.23 (0.23%)

PCG

PG&E

$6.24

-0.23 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 07

    Jan

CRL

Charles River

$131.58

1.19 (0.91%)

18:57
11/11/19
11/11
18:57
11/11/19
18:57
Hot Stocks
Charles River CEO: We are pleased with the demand curve »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.24

-0.23 (-3.55%)

18:44
11/11/19
11/11
18:44
11/11/19
18:44
Periodicals
PG&E offers $13.5B in compensation to victims of CA fires, Bloomberg says »

PG&E is offering to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Jan

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:27
11/11/19
11/11
18:27
11/11/19
18:27
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Kemet up 14.7% to $26.40…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NCLH

Norwegian Cruise Line

$51.90

0.07 (0.14%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Hot Stocks
Norwegian Cruise Line CEO: North American consumer is alive and well »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$12.58

0.07 (0.56%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Earnings
Ferro reports Q3 adjusted EPS 35c, consensus 28c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:09
11/11/19
11/11
18:09
11/11/19
18:09
Hot Stocks
Yageo to acquire Kemet for $27.20 per share in cash, or $1.8B »

Yageo and Kemet announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PAR

Par Technology

$30.23

1.07 (3.67%)

18:08
11/11/19
11/11
18:08
11/11/19
18:08
Recommendations
Par Technology analyst commentary at Jefferies »

Par Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:06
11/11/19
11/11
18:06
11/11/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Yageo to acquire Kemet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CSX

CSX

$73.93

-0.08 (-0.11%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Downgrade
CSX rating change at Deutsche Bank »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TDW

Tidewater

$17.14

-0.34 (-1.95%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Earnings
Tidewater reports Q3 adjusted EPS (99c), may not compare to consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UNVR

Univar

$23.87

-0.08 (-0.33%)

17:57
11/11/19
11/11
17:57
11/11/19
17:57
Hot Stocks
Univar named EMEA distributor for Kaopolite Abrasive in Europe »

Univar B.V., a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$46.48

0.44 (0.96%)

17:56
11/11/19
11/11
17:56
11/11/19
17:56
Hot Stocks
NexPoint Residential acquires three-property portfolio in Las Vegas for $241M »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Hot Stocks
DXC Technology to pursue strategic alternatives for three businesses »

Says as part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Earnings
Fluent lowers FY19 revenue view to $87M-$88M from $93M-$98M »

Sees adjusted EBITDA is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.